(Q44104688)

29 November 2017

The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers (English)

1 reference

29 November 2017

1 reference

1 reference

1 reference

Ann K Miller

1

1 reference

PubMed ID

12182252

29 November 2017

Robert A DiCicco

series ordinal

2

1 reference

PubMed ID

12182252

29 November 2017

Martin I Freed

series ordinal

3

1 reference

29 November 2017

1 July 2002

1 reference

29 November 2017

Clinical Therapeutics

1 reference

29 November 2017

24

1 reference

29 November 2017

7

1 reference

29 November 2017

1062-1071

1 reference

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

End-stage renal disease attributable to diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Gastrointestinal problems in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

The safety of ranitidine in over a decade of use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Glyburide-induced hypoglycemia and ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Clinical Pharmacokinetics of Ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Systemic exposure to rosiglitazone is unaltered by food

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Ranitidine bioavailability and kinetics in normal male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

Ranitidine: single dose pharmacokinetics and absolute bioavailability in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980019-4

7 January 2021

10.1016/S0149-2918(02)80019-4

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

12182252